Algert Global LLC Inozyme Pharma, Inc. Transaction History
Algert Global LLC
- $4.25 Billion
- Q4 2024
A detailed history of Algert Global LLC transactions in Inozyme Pharma, Inc. stock. As of the latest transaction made, Algert Global LLC holds 39,115 shares of INZY stock, worth $46,938. This represents 0.0% of its overall portfolio holdings.
Number of Shares
39,115Holding current value
$46,938% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding INZY
# of Institutions
104Shares Held
50.7MCall Options Held
2.6KPut Options Held
5.1K-
Adage Capital Partners Gp, L.L.C. Boston, MA5.16MShares$6.19 Million0.03% of portfolio
-
Pivotal Bio Venture Partners Investment Advisor LLC San Francisco, CA4.49MShares$5.39 Million11.45% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA4.28MShares$5.14 Million0.97% of portfolio
-
Affinity Asset Advisors, LLC New York, NY3.97MShares$4.77 Million1.97% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD3.86MShares$4.63 Million0.43% of portfolio
About Inozyme Pharma, Inc.
- Ticker INZY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,145,700
- Market Cap $48.2M
- Description
- Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...